Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions  by Peyrin-Biroulet, Laurent et al.
Clinical Gastroenterology and Hepatology 2016;14:348–354Defining Disease Severity in Inflammatory Bowel Diseases:
Current and Future DirectionsLaurent Peyrin-Biroulet,* Julián Panés,‡ William J. Sandborn,§ Séverine Vermeire,k
Silvio Danese,¶ Brian G. Feagan,# Jean-Frédéric Colombel,** Stephen B. Hanauer,‡‡ and
Beth Rycroft§§
*INSERM Unité 954 and Department of Gastroenterology, University of Lorraine, Nancy, France; ‡Hospital Clinic University of
Barcelona, Institut D’Investigacions Biomèdiques August Pi i Sunyer, Centro de Investigación Biomédica en Red en el Área
temática de Enfermedades Hepáticas y Digestivas, Barcelona, Spain; §Division of Gastroenterology, University of California San
Diego, La Jolla, California; kDepartment of Gastroenterology, University Hospital Leuven, Leuven, Belgium; ¶Division of
Gastroenterology, Istituto Clinico Humanitas, Milan, Italy; #Robarts Research Institute, University of Western Ontario, London,
Ontario, Canada; **Department of Hepatogastroenterology, Centre Hospitalier Universitaire Régional, Lille, France; ‡‡Feinberg
School of Medicine, Northwestern University, Chicago, Illinois; §§AbbVie Ltd, Maidenhead, Berkshire, United KingdomAbbreviations used in this paper: CD, Crohn’s disease; CDAI, Crohn’s
Disease Activity Index; CRP, C-reactive protein; ECCO, European Crohn’s
and Colitis Organisation; EIM, extraintestinal manifestation; ESR, eryth-
rocyte sedimentation rate; HBI, Harvey–Bradshaw Index; IBD, inﬂamma-
tory bowel disease; PRO, patient-reported outcome; QoL, quality of life;
UC, ulcerative colitis.
Most current article
© 2016 by the AGA Institute
1542-3565
http://dx.doi.org/10.1016/j.cgh.2015.06.001
Open access under CC BY-NC-ND license.Although most treatment algorithms in inﬂammatory
bowel disease (IBD) begin with classifying patients ac-
cording to disease severity, no formal validated or
consensus deﬁnitions of mild, moderate, or severe IBD
currently exist. There are 3 main domains relevant to the
evaluation of disease severity in IBD: impact of the disease
on the patient, disease burden, and disease course. These
measures are not mutually exclusive and the correlations
and interactions between them are not necessarily pro-
portionate. A comprehensive literature search was per-
formed regarding current deﬁnitions of disease severity in
both Crohn’s disease and ulcerative colitis, and the ability
to categorize disease severity in a particular patient.
Although numerous assessment tools for symptoms, qual-
ity of life, patient-reported outcomes, fatigue, endoscopy,
cross-sectional imaging, and histology (in ulcerative coli-
tis) were identiﬁed, few have validated thresholds for
categorizing disease activity or severity. Moving forward,
we propose a preliminary set of criteria that could be used
to classify IBD disease severity. These are grouped by the 3
domains of disease severity: impact of the disease on the
patient (clinical symptoms, quality of life, fatigue, and
disability); measurable inﬂammatory burden (C-reactive
protein, mucosal lesions, upper gastrointestinal involve-
ment, and disease extent), and disease course (including
structural damage, history/extension of intestinal resec-
tion, perianal disease, number of ﬂares, and extraintestinal
manifestations). We further suggest that a disease severity
classiﬁcation should be developed and validated by an in-
ternational group to develop a pragmatic means of iden-
tifying patients with severe disease. This is increasingly
important to guide current therapeutic strategies for IBD
and to develop treatment algorithms for clinical practice.
Keywords: Disease Severity; Disease Course; Inﬂammatory
Bowel Disease.
Inﬂammatory bowel diseases (IBDs) are chronicdisabling conditions. Biologics are licensed to treat
moderate-to-severe Crohn’s disease (CD) and ulcerativecolitis (UC) using randomized controlled trial deﬁnitions:
a Crohn’s Disease Activity Index (CDAI)1 score of 220 to
450 points (for CD) and a Mayo Score2 of 6 to 12 points
(including an endoscopic subscore of 2 or more points
for UC). These indices were developed to evaluate dis-
ease activity at a given time, but evaluating long-term
disease severity to guide therapeutic decisions also is
important because CD and UC are progressive disorders.
Three main domains are relevant to the evaluation of
disease severity in IBD:
(1) impact of disease on the patient: clinical symp-
toms, patient-reported outcomes (PROs), quality of life
(QoL), and disability; (2) inﬂammatory burden: extent,
location, and severity of bowel involvement at a given
time; and (3) disease course, including structural damage.
These measures are not mutually exclusive and the
correlations and interactions between them are not
necessarily proportionate.
Working deﬁnitions, but no formal validated or
consensus deﬁnitions, of mild, moderate, or severe CD or
UC currently exist.3,4
We review the evidence regarding current deﬁnitions
of disease severity in CD and UC. We conducted a
computerized search of English language publications
listed in PubMed from inception to April 2014 using
relevant medical subject headings and free text variations
of these terms (see Supplementary Information). Refer-
ence lists were hand-searched for other relevant studies.
Only studies with adult IBD populations were considered.
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International Disease Severity Deﬁnitions
Several working deﬁnitions of CD severity have
been proposed,3 primarily based on CDAI score1
(Supplementary Table 1). These classiﬁcations predom-
inantly rely on symptomology without consideration for
PROs, underlying inﬂammatory activity, structural dam-
age, or adverse prognostic factors.Impact of Disease on Patient
Clinical symptoms. The standard instrument for
evaluating clinical symptoms in CD is the CDAI.1 A
shortened and simpliﬁed version of the CDAI has shown
good agreement with the original instrument,5 as has the
PRO-2 scale, which uses 2 CDAI diary card items
(abdominal pain and stool frequency) to assess disease
activity6 (Supplementary Table 2).
The Harvey–Bradshaw Index (HBI),7 another CDAI
modiﬁcation, only requires 1 day of patient diary entries
(rather than 7 days, as required by the [short] CDAI), and
omits body weight, hematocrit level, and antidiarrheal
medication use (Supplementary Table 2). Correlation of
HBI and CDAI scores allowed the development of disease
activity thresholds (not validated).8
The CDAI and HBI correlate poorly with mucosal
inﬂammation.9,10 Therefore, the van Hees Index com-
bines clinical and laboratory data, with serum albumin
levels contributing most to the activity index,11 whereas
the Perianal Disease Activity Index12 was developed to
quantify symptoms speciﬁc to perianal ﬁstulizing disease
more adequately (Supplementary Table 2). For further
information on the burden of ﬁstulizing disease, refer to
the review by Peyrin-Biroulet et al.13
Quality of life, patient-reported outcomes, and dis-
ability. Several generic QoL tools have been shown to be
reasonably valid, reliable, and responsive in IBD pa-
tients,14,15 although QoL cut-off levels have not been
established.
PROs may become part of the required end points for
drug approval.16 Although no IBD-speciﬁc PRO instru-
ment has been formally developed and validated accord-
ing to regulatory agency guidelines, a number of indices
capture the impact of the disease on outcomes reported
by the patients, generally without differentiation between
CD and UC. These include the Inﬂammatory Bowel Dis-
ease Questionnaire,17 the Manitoba IBD Index,18 the
numeric rating scale,19 and the IBD–Control question-
naire.20 Although these indices do not have validated
thresholds to differentiate disease severity, appropriate
cut-off points have been proposed (Supplementary
Table 3). PROs obtained from CDAI diary items may be
appropriate for use in clinical trials for CD.21
Thresholds have yet to be established for instruments
looking at speciﬁc patient concerns in IBD (fatigue,stress, and anxiety/depression). The ﬁrst IBD-speciﬁc
disability index is being validated currently.22 For
further information, refer to the article by Peyrin-
Biroulet.23Inﬂammatory Burden
The state of the intestinal mucosa (location, depth,
and extent of mucosal lesions) is an important measure
of disease severity.
Biomarkers. Some biomarker cut-off values have
been described to differentiate active and inactive
disease in terms of C-reactive protein (CRP), fecal
calprotectin, fecal lactoferrin, and fecal neopterin
(Supplementary Table 4). However, it should be noted
that low CRP levels (<10 mg/L) have been reported in
patients with clinically active disease according to the
CDAI,24 although patients with low CRP and increased
CDAI generally have mild mucosal lesions.25 In addition,
CRP levels can be normal in up to one third of CD pa-
tients. Determining thresholds for fecal biomarkers to
differentiate between different disease severities can be
challenging because of variability in values depending on
methodology and intrinsic marker concentration in
different samples (biomarkers are nonspeciﬁc for IBD).
Endoscopy. Endoscopy remains the gold standard for
assessing location, depth, and extent of inﬂammatory
mucosal lesions in CD. Several endoscopic scoring sys-
tems have been developed (eg, the Crohn’s Disease
Endoscopic Index of Severity26 and the Simple Endo-
scopic Score for Crohn’s Disease).27 A more simple
approach is to classify patients according to the presence
or absence of ulcers at colonoscopy because there
remains a lack of broadly accepted or validated thresh-
olds for active disease and endoscopic remission
(Supplementary Table 5).
Cross-sectional imaging. The speciﬁcity and sensi-
tivity of ultrasound in differentiating active from inactive
disease was calculated to be 85% and 71%, respectively,
when assessed against endoscopy or surgery.28
The best known instrument for magnetic resonance
imaging is the Magnetic Resonance Index of Activity29
(see the Supplementary Information for other cross-
sectional imaging tools).Disease Course
Available deﬁnitions. The European Crohn’s and
Colitis Organisation (ECCO) consensus on the deﬁnitions
and diagnosis of CD3 suggests that some or all of the
following factors are used for typically deﬁning a severe
evolution: sustained disabling symptoms and impaired
QoL, repeated ﬂare-ups, development of irreversible
penetrating and/or stricturing lesions, need for repeated
courses of steroids, and need for surgery.
A referral center study showed that disabling CD was
deﬁned arbitrarily as having 1 of the following: required
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pitalization for disease ﬂare or complication; disabling
chronic symptoms for a cumulative time of longer than
12 months; and need for immunosuppressive therapy,
intestinal resection, or surgery for perianal disease.30 In
a subsequent study, “severe” disease was deﬁned as the
presence of 1 or more of the following criteria: complex
perianal disease, any colonic resection, 2 or more small-
bowel resections (or a single small-bowel resection
measuring >50 cm in length), or the construction of a
permanent stoma.31
“Aggressive” CD has been deﬁned as penetrating
disease, hospitalization for ﬂares or complications of the
disease, need for surgery, extraintestinal manifestations
(EIMs) involving 2 or more systems, or poor response to
currently available treatments.32 In a review focusing on
population-based cohorts, “complicated” disease was
deﬁned as the presence of bowel damage, the need for
surgery, and/or the presence of EIMs.33
A number of studies have examined prognostic fac-
tors for surgery or recurrence in CD (see Supplementary
Tables 6 and 7 for a summary, and the Supplementary
Information for further information).
Structural damage. The speciﬁcity and sensitivity of
ultrasound in the assessment of disease location and
extension were calculated to be 86% and 94%, respec-
tively, when assessed against endoscopy/other imaging
techniques or surgery.28 The sensitivity of magnetic
resonance imaging relative to capsule endoscopy for
evaluating the extent of CD lesions in the small bowel
was 74% in a pooled analysis of 2 studies, with a spec-
iﬁcity of 91%.28
The CD Digestive Damage Score (Lémann index)
measures cumulative structural bowel progression at a
speciﬁc point in an individual’s disease history.34
Ulcerative Colitis
International Deﬁnitions of Disease Severity
The American College of Gastroenterology, ECCO,4
and the Japanese Society of Gastroenterology have
graded clinical disease activity in UC into mild, moderate,
and severe disease (Supplementary Table 1). These
classiﬁcations predominantly rely on signs and symp-
toms (frequency of stools, presence of blood, tachycardia,
anemia, fever, and increased erythrocyte sedimentation
rate [ESR]), without consideration for other aspects of
disease severity. UC clinical trials have shown a lack of
consistency and clarity for deﬁning disease severity and
measures of response, with classiﬁcations confounded by
disease extent and use of concomitant medications.35
Impact of Disease on Patient
Clinical symptoms. Severe UC originally was deﬁned
as 6 or more bloody bowel movements per day, fever,tachycardia, anemia, an ESR greater than 30 mm/h, and
requirement for hospitalization.36 Although this deﬁni-
tion formed the basis for other indices that can be used
to evaluate clinical disease activity (Supplementary
Table 2), a rigorous process of item generation, reduc-
tion, and weighting was not used to develop these in-
struments, and their reported threshold disease activity
values have not been validated.
The Mayo Score2 is the best known disease activity
instrument for UC. This composite instrument is scored
on a scale from 0 to 12 and includes stool frequency,
rectal bleeding, a physician’s global assessment, and a
sigmoidoscopic evaluation. A partial Mayo Score that
omits endoscopy and correlates with the full score also
has been developed.37
Several other disease activity indices that incorpo-
rate clinical measures with sigmoidoscopy exist: the UC
Disease Activity Index38 (similar to the Mayo Score);
the Rachmilewitz Score39 (or Clinical Activity Index),
which includes 7 objective and subjectively assessed
components; and the Powell–Tuck Index40 (or the St
Mark’s Index) (Supplementary Table 2). These tools
often are used without the endoscopic component. In-
struments that rely on clinical assessment alone
include the Simple Clinical Colitis Activity Score41 (or
the Walmsley score), which shows very good correla-
tion with composite scores such as the UC Disease
Activity Index and the Powell–Tuck Index42; the
abbreviated Powell–Tuck Index,43 which includes only
self-reported items; the Lichtiger Index44; the Seo In-
dex45; and the Endoscopic–Clinical Correlation Index46
(Supplementary Table 2).
Quality of life, patient-reported outcomes, and
disability. See the section on CD for more detail.Inﬂammatory Burden
Biomarkers. Some cut-off values to differentiate
active and inactive disease have been proposed in the
literature for CRP, fecal calprotectin, and fecal neopterin
(Supplementary Table 4). The same caveats described in
relation to CD apply here.
Endoscopy. Grades of disease severity have been
proposed (but not validated) only for the Rachmilewitz
Endoscopic Index39 and the Ulcerative Colitis Endoscopic
Index of Severity47 (Supplementary Table 5).
For histology, see the Supplementary Information for
more detail.Disease Course
Available deﬁnitions. There is a lack of validated
deﬁnitions for severe or complicated UC. In a review of
predictors of aggressive UC, “severe” or complicated
disease was deﬁned as follows:32 disease that is associ-
ated with a high relapse rate (need for 2 or more courses
of steroids and/or hospitalization for ﬂares of disease
Figure 1. The interplay be-
tween the different do-
mains that govern disease
severity. (A) When discus-
sing disease severity in
IBD, it is important to
consider the impact of dis-
ease on the patient, dis-
ease burden, and disease
course. However, these
measures are not mutually
exclusive and the cor-
relations and interactions
between them are not
necessarily proportionate.
(B) Example of interplay
between domains in a hy-
pothetical patient with
asymptomatic extensive
small-bowel CD and mod-
erately active endoscopic
lesions. (C) Example of
interplay between domains
in a hypothetical patient
with an isolated, short ileal
stricture associated with
disabling obstructive sym-
ptoms. GI, gastrointestinal.
*Only for Crohn’s disease.
March 2016 Defining IBD Severity 351after initial diagnosis despite optimal treatment with
mesalamine and an immunomodulator), need for sur-
gery, development of colon cancer, and the presence of
EIMs.
Another review deﬁned “complicated” disease as the
development of colon cancer, the need for colectomy, or
the presence of EIMs.33
A number of cohort studies have identiﬁed prognostic
factors for a complicated disease course in patients
with UC (Supplementary Table 7, and Supplementary
Information).
For structural damage, see the Supplementary
Information for more detail.
Future Directions
Although most treatment algorithms in IBD begin
with classifying patients according to “disease
severity,”48 these primarily are symptom-based at a
point in time (eg, presentation) and there has been noformal consensus or validated deﬁnition regarding the
course, disease burden, or related disability of mild,
moderate, or severe CD or UC. This is problematic when
considering therapies with regulatory approval for use
according to a patient’s disease severity at a particular
time when the implication is for use according to disease
activity. As discussed, patients may have severe disease
warranting aggressive therapies even if their point-in-
time disease activity is not severe. Examples include
patients who have extensive steroid-dependent UC or CD
refractory to immunosuppressives with mild symptoms
on high doses of corticosteroids. Conversely, patients
may have severe symptoms without evidence of active
inﬂammation. Indeed, approximately 20% of patients
entered into the Crohn’s disease clinical trial evaluating
inﬂiximab in a new long term treatment regimen and
study of biologic and immunomodulator naive patients in
Crohn’s disease studies based on moderate–severe CDAI
scores had no evidence of mucosal disease at
colonoscopy.
Table 1. Proposed Potential Criteria to Classify Disease
Severity in Inﬂammatory Bowel Disease
Impact of the disease on the patient
Clinical symptoms
Quality of life
Fatigue
Disability
Inﬂammatory burden
C-reactive protein
Mucosal lesions
Upper gastrointestinal involvementa
Disease extent
Disease course
Structural damage
History/extension of intestinal resection
Perianal diseasea
Number of ﬂares
Extraintestinal manifestations
aCrohn’s disease only.
352 Peyrin-Biroulet et al Clinical Gastroenterology and Hepatology Vol. 14, No. 3Organizations such as ECCO and the American Col-
lege of Gastroenterology recently have proposed
working deﬁnitions of CD and UC disease severity for
use in clinical practice; however, these predominantly
rely on symptoms. When discussing disease severity in
either CD or UC, it is important to think beyond clinical
symptoms to include other factors important to the
patient (PROs, QoL, and disability), as well as disease
burden and structural damage. In many patients, re-
lationships between these measures may be evident.
For example, patients with mild IBD may have mild
symptoms, low levels of disability and fatigue, and mild
mucosal lesions. Conversely, patients with severe dis-
ease may have severe symptoms, experience high levels
of disability and fatigue, and have extensive and/or
deep lesions. However, the interplay between these
domains is not necessarily proportionate—each needs
to be considered separately and as part of the whole
patient proﬁle (Figure 1). For example, patients with
anorectal CD may experience moderate symptoms but
have a low inﬂammatory burden and no risk factors for
a complicated disease course; patients with an ileal
stricture may have symptoms but very limited disease
extension; steroid-dependent patients may have high
disease activity but a minimal disease burden and a
moderately complicated course of disease; patients with
symptoms such as fecal incontinence may experience a
more severe disease course owing to their impact on
daily life and activities, as may asymptomatic patients
with disease complications such as dysplasia and can-
cer. Importantly, disease activity should be distin-
guished from disease severity even though disease
activity may contribute to the severity of IBD via clinical
symptoms and impact on PROs. Patients may experi-
ence a noncomplicated or a complicated disease course
not necessarily related to their disease activity at a
given time. In addition, patients with IBD may experi-
ence irritable bowel syndrome–type symptoms,49 sug-
gesting that IBD and irritable bowel syndrome are notmutually exclusive and may co-exist in a considerable
number of IBD patients.
As we have reviewed, placing a value on disease
severity is inherently difﬁcult in IBD and is hampered by
a lack of validated instruments with discrete thresholds.
Therefore, we propose developing a disease severity
classiﬁcation for IBD including the 3 main domains that
inﬂuence severity based on potential criteria such as
those listed in Table 1. Future efforts are needed to
develop a pragmatic means of classifying patients within
the spectrum of disease severity.
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Search Strategy
Studies evaluating tools to assess disease activity,
disease burden, and PROs were identiﬁed using the
following medical subject heading terms: “inﬂammatory
bowel diseases,” “Crohn disease,” “colitis, ulcerative,”
“severity of illness index,” “questionnaires,” “reproduc-
ibility of results,” “sensitivity and speciﬁcity.” Free text
variations of these terms also were used. Studies were
included if they described a tool with a threshold or cut-
off values to differentiate between mild, moderate, and
severe disease. Studies evaluating prognostic factors for
a complicated disease course were identiﬁed using the
following medical subject heading terms: “inﬂammatory
bowel diseases/epidemiology OR /complications,”
“Crohn disease/epidemiology OR /complications,” “coli-
tis, ulcerative/epidemiology OR /complications,” “risk
factors,” “disease progression.” Free text variations of
these terms also were used.Thresholds for Disease Activity Identiﬁed
in the Literature
Cross-sectional imaging in Crohn’s disease. The Sono-
graphic Lesion Index for CD was developed for small-
intestine contrast ultrasonography.1 This tool evaluates
bowel wall thickness, lumen diameter, lesion length, and
number of lesion sites. Fistula, mesenteric adipose tissue
alteration, abscesses, and lymph nodes also are consid-
ered. An algorithm was generated to provide an index
value ranging from 0 to 200. This score was subdivided
into 5 classes, indicating different levels of disease
severity. Ripolles et al2 compared contrast-enhanced ul-
trasound with endoscopy for determining disease
severity and found that a 46% increase in threshold
brightness was able to predict moderate or severe dis-
ease (sensitivity, 96%; speciﬁcity, 73%; positive predic-
tive value, 92%; and negative predictive value, 85%). In
terms of magnetic resonance imaging, Rimola et al3,4
developed the Magnetic Resonance Index of Activity, an
instrument that scores wall thickness, relative contrast
enhancement, edema, and ulcers in different segments of
the gastrointestinal tract. Mucosal healing is deﬁned as a
segmental score less than 7 and ulcer healing is deﬁned
as a segmental score less than 11. Another index based
on qualitative evaluation of magnetic resonance imaging
ﬁndings including contrast enhancement, edema, wall
thickening, ulcers, presence of a layered pattern, and
diffusion hyperintensity found that a segmental magnetic
resonance score greater than 2 detected endoscopic
inﬂammation in the colon with a sensitivity and speci-
ﬁcity of 58% and 84%, respectively.5 Gallego et al6
modiﬁed a scoring system developed by Girometti
et al7 to develop a magnetic resonance imaging instru-
ment that measured bowel wall thickness, relativeenhancement, motility, percentage of stenosis, bowel
wall edema, mucosal abnormalities, lymph nodes,
ﬁstulae, and inﬂammatory masses to provide a cumula-
tive score ranging from 0 to 12. Based on correlation
with Simple Endoscopic Scale CD, ileal disease was
classiﬁed as inactive (0–2), mild (3–6), or moder-
ate–severe (7). Finally, a magnetic resonance enter-
ography index was identiﬁed, which evaluated recurrent
transmural inﬂammation in the ileum and is based on a
scoring system from 0 (no ﬁndings) to 3 (severe recur-
rence with transmural and extramural changes).8–10
Cross-sectional imaging in ulcerative colitis. Several
grading tools have been developed for cross-sectional
imaging in UC, including the Tsuga colorectal ultra-
sound criteria,11 and a simpliﬁed magnetic resonance
colonography index that can detect endoscopic in-
ﬂammations (score, 1) or severe lesions (score,
2).12 Another index based on qualitative evaluation of
magnetic resonance imaging ﬁndings including
contrast enhancement, edema, wall thickening, ulcers,
presence of a layered pattern, and diffusion hyper-
intensity found that a segmental magnetic resonance
score greater than 1 detected endoscopic inﬂammation
in the colon with a sensitivity and speciﬁcity of 89%
and 86%, respectively.5
Histology in ulcerative colitis. A growing body of evi-
dence suggests that histologic healing is associated with
better clinical outcomes in UC, including decreasing the
risk of colorectal cancer.13 Several scoring systems exist
for the assessment of histologic disease activity in UC,
including the Riley scale,14 the Geboes score,15 a modi-
ﬁed Riley and Geboes scale,16 the Histologic Activity In-
dex,17 and the Endocytoscopy System Score.18 However,
none of these scoring systems have been validated and
correlation between histologic grade and disease activity
or severity has not been shown. No thresholds for
differentiating between different levels of disease activity
or severity were identiﬁed in the literature.
Structural damage in ulcerative colitis. A growing body of
evidence indicates that UC is also a progressive disease.
A review of the literature found that disease progression
involves proximal extension, stricturing, pseudopoly-
posis, dysmotility, anorectal dysfunction, and impaired
permeability, although the true prevalence and relevance
of these complications in clinical practice has yet to be
established.19
Inﬂammatory lesions in UC are conﬁned to the colon
and mainly affect the inner wall layer of the gastroin-
testinal tract; therefore, cross-sectional imaging is not
used as widely for the diagnosis or monitoring in this
condition as it is in CD. Nevertheless, there are some UC
patients in whom cross-sectional imaging provides
important information relating to disease severity, such
as those with tight strictures or high risk of perforation
that makes endoscopy difﬁcult. Although several grading
tools have been developed for cross-sectional imaging in
UC (see earlier), validated cut-off values for extent of
disease severity are lacking.
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Disease Course in Crohn’s Disease
Two important cohort studies have evaluated prog-
nostic factors for a disabling disease course in CD20,21
(Supplementary Table 6) and have used these factors
to develop predictive indices for disabling disease.
Beaugerie et al20 created the Beaugerie Index (known as
the St Antoine Model), which ranges from a score of
0 (no independent predictors present) to 3 (all 3 inde-
pendent predictors present). In the Beaugerie et al20
initial cohort, a score of 2 or 3 provided a positive pre-
dictive value of 91% and 93%, respectively, for disabling
disease. This was validated in a prospective population
of 302 patients, with respective positive predictive
values of 84% and 91% for scores of 2 and 3. Loly et al21
developed a similar index, in which the presence of at
least 2 independent risk factors had sensitivity, speci-
ﬁcity, positive predictive values, and negative predictive
values of 34%, 78%, 68%, and 46%, respectively, for
predicting disabling disease at 5 years after diagnosis.
When Loly et al21 extended their analysis into prognostic
factors for a severe disease course (Supplementary
Table 6), the presence of both identiﬁed risk factors at
diagnosis had a sensitivity, speciﬁcity, positive predictive
value, and negative predictive value of 17%, 98%, 78%,
and 69%, respectively.
A number of other studies also have looked at
prognostic factors for surgery or recurrence in CD
(Supplementary Table 7). A prospective Norwegian
population-based cohort of new cases of CD with follow-
up evaluation at 10 years after diagnosis investigated
factors present at diagnosis that predict subsequent
surgery.22 In an adjusted Cox regression analysis, age at
diagnosis again was identiﬁed as an important prog-
nostic factor: those aged 40 years and older had half the
likelihood of needing surgery during the follow-up
evaluation than those younger than age 40 years (haz-
ard ratio, 0.5; 95% conﬁdence interval, 0.3–0.9). Isolated
colonic or ileocolonic disease was protective against
surgery relative to disease in the terminal ileum (hazard
ratio, 0.3; 95% CI, 0.2–0.6; hazard ratio, 0.3; 95% con-
ﬁdence interval, 0.2–0.5, respectively), and stricturing or
penetrating disease notably increased the risk of surgery
(hazard ratio, 2.3; 95% conﬁdence interval, 1.3–4.1;
hazard ratio, 5.4; 95% conﬁdence interval, 3.0–9.9,
respectively). Smoking and systemic steroid use were
not identiﬁed as risk factors. Another cohort study
based on a population from Olmsted County, Minnesota,
also evaluated predictors of surgery in patients with
CD.23 In a regression model that included patients with
at least 90 days of follow-up evaluation after diagnosis
and who had not had a ﬁrst major abdominal surgery
within 90 days of the diagnosis, the following factors
were identiﬁed as predictors of time to surgery: male
sex (hazard ratio, 1.6; 95% conﬁdence interval,
1.02–2.4), current smoking (hazard ratio, 1.7; 95%conﬁdence interval, 1.1–2.7), penetrating disease
behavior (hazard ratio, 2.8; 95% conﬁdence interval,
1.1–6.7), and corticosteroid use within 90 days of the
diagnosis (hazard ratio, 1.6; 95% conﬁdence interval,
1.03–2.5). In addition, relative to colonic disease extent,
ileocolonic disease (hazard ratio, 3.3; 95% conﬁdence
interval, 1.8–5.8), small-bowel disease (hazard ratio, 3.4;
95% conﬁdence interval, 1.9–6.1), and gastroduodenal
disease (hazard ratio, 4.0; 95% conﬁdence interval,
1.2–13.8) all were associated with a shorter time to
surgery. These ﬁndings validate those seen in other
cohort studies.24–26
Studies also have focused on identifying potential
prognostic factors for disease recurrence. In an analysis
of patients randomized to placebo in the National
Cooperative Crohn’s Disease study, multivariate analysis
found that use of corticosteroids before study entry,
partial resection with disease persistence, perianal dis-
ease, and CDAI score of 200 or greater were predictors of
short-term relapse.27 In a prospectively assembled
European population-based cohort of 358 CD patients,
upper gastrointestinal disease at diagnosis had an excess
risk of surgical or medical recurrence, whereas age of at
least 40 years at diagnosis was protective against
recurrence and colonic disease was protective specif-
ically against resection.28 Analysis of a Danish
population-based registry evaluating the risk of medical
or surgical recurrence found that age at diagnosis had a
hazard ratio per 10-year period of 0.89 (95% conﬁdence
interval, 0.84–0.95), suggesting that the risk of recur-
rence decreased by 11% per decade of follow-up evalu-
ation.29 Current smoking was also a negative prognostic
factor for disease recurrence or a severe disease
course.29 In a study in New Zealand, Tarrant et al30
found that perianal disease was a signiﬁcant predictor
of change in CD phenotype. Interestingly, no association
between familial disease and subsequent disease course
severity has been reported.31
Biomarkers also may play a role in predicting a
complicated disease course. For example, an increased
CRP level at diagnosis predicts future surgery (in pa-
tients with ileal disease)32 and 1-year relapse,33 and an
increased level during a relapse predicts subsequent
relapse during the year.34 The presence of anti–S cer-
evisiae antibodies at diagnosis has been associated with
a higher risk of more severe disease behavior during
follow-up evaluation or risk of surgery.26,35–37 In addi-
tion, genetic markers may be useful predictors of future
disease patterns: several mutations of the NOD2/
CARD15 gene increase the risk of small-bowel stenosis
and the need for early surgery.38–41 A retrospective
study including 1528 patients with CD with more than
10 years of follow-up evaluation from 8 European
referral hospitals identiﬁed the Nucleotide-binding
oligomerization domain-containing protein 2 gene as
the most important genetic prognostic factor in CD.
Nucleotide-binding oligomerization domain-containing
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Supplementary Table 1. International Deﬁnitions of Disease Activity in Crohn’s Disease and Ulcerative Colitis
Crohn’s disease (international deﬁnitions based on CDAI parameters1)
ACG2 Symptomatic remission Mild–moderate Moderate–severe Severe/fulminant
CDAI <150
Asymptomatic/without symptomatic
inﬂammatory sequelae
May have responded to medical or
surgical therapy and have no
residual active disease
Does not include patients who require
corticosteroids
CDAI 150–220
Ambulatory
Able to tolerate oral alimentation without
manifestations of dehydration, systemic
toxicity (high fevers, rigors, and
prostration), abdominal tenderness,
painful mass, intestinal obstruction,
or >10% weight loss
CDAI 220–450
Failed to respond to treatment for
mild–moderate disease
or
Has more prominent symptoms of fever,
signiﬁcant weight loss, abdominal pain
or tenderness, intermittent nausea or
vomiting (without obstructive ﬁndings),
or signiﬁcant anemia
CDAI >450
Persistent symptoms despite treatment with
corticosteroids/biologics as outpatients
or
Has high fevers, persistent vomiting,
intestinal obstruction, signiﬁcant peritoneal
signs, cachexia, or abscess
ECCO3 Symptomatic remission Mild Moderate Severe
CDAI <150 CDAI 150–220
Ambulatory
Eating and drinking
<10% weight loss
No obstruction, fever, dehydration,
abdominal mass, or tenderness
CRP increased above ULN
CDAI 220–450
Intermittent vomiting or weight loss >10%
Treatment for mild disease ineffective or
tender mass
No overt obstruction
CRP increased above ULN
CDAI >450
Cachexia or evidence of obstruction/abscess
Persistent symptoms despite intensive treatment
CRP increased
Ulcerative colitis (international deﬁnitions based on Truelove–Witts criteria)4
ACG5 Symptomatic remission Mild Moderate Severe Fulminant
<4 stools/d (with or without blood)
No systemic signs of toxicity
Normal ESR
4 stools/d
Minimal signs of toxicity
6 bloody stools/d
Signs of toxicity (fever,
tachycardia, anemia)
Increased ESR
10 stools/d
Continuous bleeding
Toxicity
Abdominal tenderness
and distension
Blood transfusion
requirement
Colonic dilation on
abdominal plain ﬁlms
ECCO6 Symptomatic remission Mild Moderatea Severeb
<4 stools/d without bleeding
or urgency
<4 bloody stools/d
Pulse <90 bmp
Temperature <37.5C
Hemoglobin >11.5 g/dL
ESR <20 mm/h or normal CRP
4 bloody stools/d if
Pulse 90 bmp
Temperature 37.8C
Hemoglobin 10.5 g/dL
ESR 30 mm/h or CRP 30 mg/dL
6 bloody stools/d and
Pulse >90 bmp
Temperature >37.8C
Hemoglobin <10.5 g/dL
ESR >30 mm/h or CRP >30 mg/dL
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JSG Symptomatic remission Mild Moderate Severe
4 stools/d (with or without blood)
Pulse <90 bmp,
Temperature <37.5C
Hemoglobin >10.5 g/dL
Normal ESR
Not speciﬁcally deﬁned; symptoms
that fall between mild and severe
6 bloody stools/d
Pulse 90 bmp
Temperature 37.5C
Hemoglobin 10.5 g/dL
ESR 30 mm/h
Patients must meet at least 4 of these conditions,
including 6 bloody stools/d and either
pulse 90 bmp, or temperature 37.5C
bmp, beats per minute.
ACG, American College of Gastroenterology; JSG, Japanese Society of Gastroenterology; ULN, upper limit of normal.
aModerate disease was deﬁned as between mild and severe.
bECCO prefers the term “severe colitis” to “fulminant colitis” because the latter is outdated and refers to a single episode progressing to death within 1 year.
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Supplementary Table 2. Thresholds for Disease Activity for Symptom-Based Scoring Systems in Crohn’s Disease and
Ulcerative Colitis
Tool Parameters assessed Scoring system
Activity score thresholds
Remission Mild Moderate Severe
Crohn’s disease
Short CDAI7,8 Soft stool frequency over past week
Abdominal pain over past week
General well-being over past week
Cumulative score with
components given
different weightings
(+ constant to yield a
mean value as close as
possible to full CDAI)
<150a,b 150–219 220–450 >450
PRO-29 Soft stool frequency over past week
Abdominal pain over past week
Cumulative score with
components given
different weightings
<8 8–13 14–34 >35
HBI10,11 General well-being on previous day
Abdominal pain on previous day
Liquid stool frequency on previous
day
Abdominal mass
EIMs
Cumulative score <5c 5–7 8–16 >16
van Hees index12 Albumin
ESR
Body mass index
Abdominal mass
Sex
Temperature
Stool consistency
Resection
Extraintestinal lesions
Cumulative score with
components given
different weightings
<100 100–149 150–210 >210
PDAI13 Patient report of perianal discharge
Pain with restriction of daily activities
Restriction of sexual activity
Type of perianal disease
Degree of induration
Cumulative score with
each component score
on a scale from 0 (no
symptoms) to 4 (severe
symptoms)
014 <414 (inactive
disease not
requiring
therapy)
414 (active disease
requiring medical
or surgical
therapy)
Ulcerative colitis
Mayo score15 Stool frequency
Rectal bleeding
Physician’s global assessment
Sigmoidoscopy
Cumulative score 0–2d 3–5 6–10 11–12
UCDAI16,17 Stool frequency
Rectal bleeding
Physician’s global assessment
Sigmoidoscopy
Cumulative score 0–2e 3–8 9–12
Rachmilewitz score
(CAI)18,19
Bowel movement frequency
Blood in stools
Physician’s global assessment
Abdominal pain/cramps
Temperature
EIMs
Laboratory ﬁndings (ESR,
hemoglobin)
Cumulative score 0–4 5–10 11–17 >17
Powell–Tuck index
(St Mark’s
index)20,21
Well-being
Abdominal pain
Bowel movement frequency
Stool consistency
Bleeding
Anorexia
Nausea/vomiting
Abdominal tenderness
Eye, joint, mouth, or skin
complications
Temperature
Sigmoidoscopy
Cumulative score 3f 4–10 11–14 >14
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Supplementary Table 2. Continued
Tool Parameters assessed Scoring system
Activity score thresholds
Remission Mild Moderate Severe
SCCAI (Walmsley)22 Bowel movement frequency (day)
Bowel movement frequency (night)
Urgency of defecation
Blood in stool
Well-being
Extracolonic features
Cumulative score 222,23
<2.524
3–20
Lichtiger index25,26 Diarrhea frequency
Nocturnal diarrhea
Visible blood (% of movements)
Fecal incontinence
Abdominal pain/cramping
Well-being
Abdominal tenderness
Need for antidiarrheal medications
Cumulative score 3 4–8 9–14 >14
Seo index27,28 Bowel movement frequency
Blood in stool
ESR
Hemoglobin
Albumin
Cumulative score with
components given
different weightings
(+ constant to yield a
mean value as close as
possible to Truelove–
Witts criteria)
<10829
<12024
<150 150–220 >220
CAI, Clinical Activity Index; PDAI, Perianal Disease Activity Index; SCCAI, Simple Clinical Colitis Activity Index; UCDAI, Ulcerative Colitis Disease Activity Score.
aOne study suggested that a CDAI cut-off value of 55 is more precise for identifying patients in endoscopic remission (sensitivity of 71% and speciﬁcity of 64%).30
bA CDAI score exceeding 150 appears an appropriate cut-off value for deﬁning symptomatic disease in patients with postoperative recurrence; however,
sensitivity and speciﬁcity were relatively low at 70% and 81%, respectively, with a positive predictive value of 50% and a negative predictive value of 91%.31
cOne study suggested that an HBI cut-off value of 1 is more precise for identifying patients in endoscopic remission.30
dOne study suggested that a full score less than 4 is more precise for identifying patients in patient-deﬁned remission.32
eOne study found that the optimal cut-off value for patient-deﬁned remission with the UCDAI was less than 2.5 points, which had a sensitivity and speciﬁcity of
82% and 89%, respectively.24
fOne study suggested that a Powell–Tuck score of 4 is more precise for identifying patients in endoscopic remission,23 and another study found that a score of less
than 3.5 correlates best with patient-deﬁned remission.24
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Supplementary Table 3. Thresholds for Disease Activity for Patient-Reported Outcome Indices in Inﬂammatory Bowel
Diseases
Tool Parameters assessed Scoring system Thresholds for disease severity
IBDQ33–35 32 questions relating to bowel
symptoms, systemic symptoms,
emotional function, and social
function
Extended version available with 36
questions
Each question is scored on a Likert
scale from 1 (worst) to 7 (best),
providing a total score of 32–224
(36–252 in the extended version)
Cut-off value of 168 points is
predictive of CDAI-deﬁned
remission in CD36
Cut-off value of 205 points is
predictive of patient-deﬁned
remission in UC24
In extended version, a cut-off value of
209 points predicted normal
quality of life according to
EQ-5D37
Manitoba IBD
Index38
Single-item scale related to self-reported
symptom persistence for the
previous 6 months
6-level scale ranging from a, my
disease has been constantly
active, to f, I was well in the past
6 months, what I consider a
remission or absence of
symptoms
Disease considered active if
symptoms experienced for 1–2
days/mo (score, a–d)
Numeric rating
scale39
Single-item scale related to self-reported
overall perception of health
11-point scale ranging from 0, as bad
as being dead, to 10, perfect
health
Patients who believed that they were
in remission typically had a
numeric rating scale score of 6
IBD–Control
Questionnaire40
13 categoric items relating to disease
control, satisfaction with treatment,
pain, energy, and social, emotional,
and physical function
100-mm VAS in which patients rate their
perceived level of disease control
Scores range from 0–16, with higher
scores indicating better control
VAS ranges from 0 (complete control)
to 100 (worst control)
Cut-off value of 13 points on
questionnaire and 85 points on
VAS identiﬁed patients with
quiescent disease
EQ-5D, EuroQol-5D; IBDQ, Inﬂammatory Bowel Disease Questionnaire; VAS, visual analog scale.
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Supplementary Table 4. Accuracy of Biomarkers to Predict Disease Activity or Severity in Patients With Crohn’s Disease and Ulcerative Colitis
Biomarker Study Patients, N
Assessment of
disease activity/severity
Biomarker
cut-off Sensitivity, % Speciﬁcity, %
Positive
predictive value, %
Negative predictive
value, %
Crohn’s disease
CRP Chamouard et al41 150 van Hees Index <150 4 mg/L 44 100 100 66
CDAI <220 4 mg/L 49 88 90 46
Karoui et al42 103 CDAI 220 <19 mg/L 76 56
Sipponen et al43 77 CDEIS <3 <5 mg/L 48 91 91 48
Schoepfer et al44 122 SES-CD <4 <5 mg/L 68 58 88 29
af Bjorkesten et al30 64 SES-CD 2 3 mg/L 50 24
Nancey et al45 78 SES-CD <2 <5 mg/L 46 86 78 61
Fecal calprotectin Sipponen et al43 77 CDEIS <3 <200 mg/g 70 92 94 61
CDEIS 3–9 <1000 mg/g 69 93 82 87
af Bjorkesten et al30 64 SES-CD 2 94 mg/g 84 74
Schoepfer et al44 122 SES-CD <4 <70 mg/g 89 72 88 76
D’Haens et al46 87 No ulcers <250 mg/g 52 83 89 38
No ulcers >5 mm <250 mg/g 60 80 78 62
CDEIS <3 <250 mg/g 94 62 49 97
Nancey et al45 78 CDEIS <3 <250 mg/g 71 78 79 71
Fecal lactoferrin Sipponen et al43 77 CDEIS <3 <10 mg/g 66 92 94 59
CDEIS 3–9 <50 mg/g 65 96 87 83
Fecal neopterin Nancey et al45 78 SES-CD 2 <200 pmol/g 74 73 73 74
Ulcerative colitis
CRP Nancey et al45 55 Rachmilewitz score <2 <5 mg/L 63 100 100 55
Schoepfer et al26 228 Modiﬁed Baron Score <2 <6 mg/L 68 72
Fecal calprotectin D’Haens et al46 39 Mayo Endoscopic subscore 1–3 <250 mg/g 71 100 100 47
Mayo Endoscopic subscore 2–3 <250 mg/g 86 78 82 82
Schoepfer et al26 228 Modiﬁed Baron score <2 <57 mg/g 91 90
Nancey et al45 55 Rachmilewitz score <2 <250 mg/g 91 87 87 91
Fecal neopterin Nancey et al45 55 Rachmilewitz score <2 <200 pmol/g 74 100 100 73
Husain et al47 52 SCCAI <5 <98.4 ng/g 88 82
CDEIS, Crohn’s Disease Endoscopic Index of Severity; SCCAI, Simple Clinical Colitis Activity Index; SES-CD, Simple Endoscopic Scale–Crohn’s Disease.
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Supplementary Table 5. Thresholds for Disease Activity for Endoscopic Scoring Systems in Crohn’s Disease and Ulcerative Colitis
Tool Parameters assessed Scoring system
Activity score thresholds
Remission Mild Moderate Severe
Crohn’s disease
CDEIS43,48,49 Deep ulceration, superﬁcial ulceration, surface
involved by disease, and ulcerated surface
scored in up to 5 segments (rectum, sigmoid
and left colon, transverse colon, right colon,
and ileum)
Presence/absence of ulcerated stenosis
Cumulative score adjusted for the
number of segments totally or
partially explored (maximum
score, 44)
0–3 3–9 9–12 12
SES-CD50,51 Presence and size of ulcers, extent of the
ulcerated surface, extent of the affected
surface, and the presence and type of
narrowings scored in up to 5 segments
(rectum, sigmoid and left colon, transverse
colon, right colon and ileum)
Cumulative score (maximum
score, 56)
0–2 3–6 7–15 16
Lewis score52 (capsule endoscopy) Villous edema and ulcer scored in the ﬁrst,
second, and third tertiles
Stenosis for the whole study
Cumulative score with different
weightings given according to
number, longitudinal extent,
and descriptors
<135 135–790 >790
Ulcerative colitis
Rachmilewitz score18,19 Granulation, vascular pattern, vulnerability of
mucosa, and mucosal damage
Cumulative score with different
weightings given according to
number, longitudinal extent,
and descriptors
<4 4–6 6–9 9–12
UCEIS53 Vascular pattern, bleeding, erosions, and ulcers Cumulative score with each
parameter graded on a scale
of 1–4
1 on all
descriptors
3 for vascular pattern
and bleeding with
2 for erosions and
ulcers
CDEIS, Crohn’s Disease Endoscopic Index of Severity; SES-CD, Simple Endoscopic Score for Crohn’s Disease; UCEIS, Ulcerative Colitis Endoscopic Index of Severity.
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Supplementary Table 6. Independent Prognostic Factors for a Disabling or Severe Disease Course in Crohn’s Disease:
Findings From Two Large Cohort Studies
Factors in Cox regression model Publication Independent prognostic factors Degree of risk
Prognostic factors for disabling disease in the 5-year period after diagnosis
Sex
Ethnicitya
Age at onset
Location of disease at diagnosis
Previous appendectomy
Smoking status
Systemic manifestations at diagnosis
Perianal lesions at diagnosis
Initial requirement for steroids
Beaugerie et al,54 Initial requirement for steroids
Age at diagnosis < 40 y
Perianal lesions at diagnosis
OR, 3.1 (95% CI, 2.2–4.4)
OR, 2.1 (95% CI, 1.3–3.6)
OR, 1.8 (95% CI, 1.2–2.8)
Loly et al,55 2008 Initial requirement for steroids
Perianal lesions at diagnosis
Ileocolonic location of disease
OR, 1.7 (95% CI, 1.0–2.7)
OR, 2.6 (95% CI, 1.4–5.1)
OR, 1.7 (95% CI, 1.1–2.8)
Prognostic factors for severe disease in the 5-year period after diagnosis
Earlier-listed factors and
Family history
Weight loss > 5 kg at diagnosis
Fever (>38C) at diagnosis
Stricturing behaviour at diagnosis
Intra-abdominal penetrating behavior
Leukocyte count
Platelet count
Hemoglobin
C-reactive protein
Albumin
Ferritin
CARD-15 genotype for 3 main
mutations, ASCA
pANCA
Loly et al,55 2008 Stricturing behavior
Weight loss > 5 kg
HR, 2.1 (95% CI, 1.4–3.2)
HR, 1.7 (95% CI, 1.1–2.4)
ASCA, anti–S cerevisiae antibodies; HR, hazard ratio; OR, odds ratio; pANCA, perinuclear antineutrophil cytoplasmic antibodies.
aEthnicity was not a covariate in the study by Loly et al55 because only 5 patients in the study were not Caucasian.
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Supplementary Table 7. Prognostic Factors for a Severe or Complicated Disease Course in Patients With Crohn’s Disease
and Ulcerative Colitis
Prognostic factor Outcome
Crohn’s disease
Age <40 y at diagnosis Disabling disease at 5 years54
Surgery56,57
Disease recurrence58,59
Weight loss > 5 kg at diagnosis Severe disease at 5 years55
Small-bowel disease location Surgery60–62
Disabling disease at 5 years55
Time to complicated disease63,64
Ileocolonic disease location Disabling disease at 5 years55
Surgery60–62
Upper gastrointestinal disease location Surgery60,62
Disease recurrence59
Severe endoscopic disease at diagnosis Penetrating complications65
Surgery65
Perianal disease at diagnosis Surgery69
Disease recurrence66,67
Disabling disease at 5 years54,55
Complicated disease phenotype63
Stricturing or penetrating disease at diagnosis Severe disease at 5 years55
Surgery56,57,60,61,68
Initial requirement for steroids Disease recurrence66
Time to complicated disease64
Disabling disease at 5 years54,55
Surgery60
Current smoking Surgery60,62,69
Disease recurrence58
CDAI score >200 Disease recurrence66
Increased CRP level Surgery (in patients with ileal disease)57
Disease recurrence67,70
Presence of ASCA Severe/complicated disease behavior71,72
Surgery68,73
NOD2/CARD15 mutations Risk of small-bowel stenosis and need for early surgery74–77
Ulcerative colitis
Younger age at diagnosis Relapse58,78
Number of relapses79,80
Colectomy57
Colorectal cancer81–83
Extensive disease Colectomy84,85
Colorectal cancer81,82
Disease recurrence58
Disease location Colectomy69
Diagnosis of primary sclerosing cholangitis Colorectal cancer83
Increased ESR Colectomy84
Presence of pANCA Relapse86
Presence of ASCA Relapse86
Increased CRP level Colectomy (in patients with extensive disease)57
Increased fecal calprotectin level Relapse78
Negative smoking status Colectomy69
Relapse80
ASCA, anti–S cerevisiae antibodies; pANCA, perinuclear antineutrophil cytoplasmic antibodies.
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